Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Veradermics, Inc (MANE)

Veradermics reports positive 12-month Study '302' data for VDPHL01 in male hair loss

Positive Impact 4 of 5 product/contract

Veradermics reported positive topline 12-month results from Part B of Study '302', a Phase 2/3 trial of its lead candidate VDPHL01 in 519 men with mild-to-moderate pattern hair loss, and reported no new safety signals. The filing covers clinical trial data only and includes no revenue, earnings, or guidance figures, and the drug has not been approved for sale.

Key points

  • Non-vellus hair count rose 43.9 hairs/cm2 (twice daily) and 29.7 hairs/cm2 (once daily) from baseline to Month 12 in the continued group.
  • At Month 12, 89.1% (twice daily) and 79.8% (once daily) of continued-group participants reported visible improvement in hair coverage on the AAIRS scale.
  • No treatment-related serious adverse events and no adverse event-related study discontinuations were reported between Month 6 and Month 12.
  • The company plans to announce data from Study '306' in women in the first half of 2027.

The filing

CompanyVeradermics, Inc (MANE)
Form8-K, current report
Filed with the SECNov 9, 2026, 9:04 AM ET
Accession number0001827635-26-000038

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 9:18 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.